NC-TRANSENTERIX

TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it will exhibit and feature the Senhance Surgical Robot (“the Senhance” or “the Senhance system”) at the 25th Annual Congress of the European Society of Gynaecological Endoscopy (ESGE). The congress will be held on October 2-5, 2016 in Brussels, Belgium.

Dr. Salvatore Gueli Alletti, a gynecologic oncologist at the Gemelli Hospital of the Catholic University of the Sacred Heart in Rome, Italy, will give a lecture on the Senhance system. The lecture, titled, “Initial clinical experience with a surgical robotic system incorporating laparoscopic motion, force sensing instrumentation, and eye-sensing camera control,” will be held on October 5, 2016, at 11:30am CEST.

“With the Senhance, gynecologic applications have become one of the leading procedural focuses for TransEnterix,” said Todd M. Pope, President and CEO of TransEnterix.”Gynecologists are welcoming this new robotic option with haptic force feedback, eye-sensing camera control, and compelling procedural costs. We look forward to further showcasing the Senhance’s unique features at this year’s congress.”

The Senhance will be available for surgeon evaluations at the congress. The Senhance carries the CE Mark for use in general surgery, gynecology, urology and thoracic surgery. TransEnterix is actively preparing a submission for U.S. FDA Clearance for the Senhance.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com .

Forward-Looking Statements

This press release includes statements relating to The Senhance™ Surgical Robotic System and the SurgiBot™ System and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether gynecologists are welcoming the new robotic option (of Senhance) with haptic force feedback, eye-sensing camera control and compelling procedural costs. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160929005315/en/

Contact:

For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media Contact:
(For EU) Conrad Harrington, +44 (0)20 3178 8914
or
(For US) Hannah Dunning, +1 415-618-8750
TransEnterix-SVC@sardverb.com

Link:

ClickThru